

REMARKS

Enclosed herewith as a separate paper is a substitute specification that has been prepared to place the application in better conformance with U.S. practice. The present amendment has been introduced to place the claims in a better condition for examination, and to make the sequences listed in the claims correspond with the sequences submitted herewith.

In accordance with 37 CFR 1.825, a substitute sequence listing in computer readable form, as well as a paper copy, is also submitted herewith. The undersigned hereby certifies that the sequence listing (i.e., the substitute sheets and computer readable form) contain no new matter. Support for the sequence listing can be found in the original application, at least on pages 2, 3, 6, and 14. The undersigned further certifies that the copy of the sequence listing in computer readable form is the same as the substitute copy of the sequence listing. If necessary, the Office is hereby instructed to insert the sequence listing into the application


Attached hereto is a marked-up version of the changes made to the application by the present Amendment.

In light of the foregoing, it is respectfully submitted that the present application is in a condition for allowance and notice to that effect is hereby requested. If it is determined that the application is not in a condition for allowance, the Examiner is invited to initiate a telephone interview with the undersigned attorney to expedite prosecution of the present application.

If there are any additional fees resulting from this communication, please charge same to our Deposit Account No. 18-0160, our Order No. SCH-32409.

Respectfully submitted,

RANKIN, HILL, PORTER & CLARK LLP

By: 
David E. Spaw, Reg. No. 34732

700 Huntington Building
925 Euclid Avenue
Cleveland, Ohio 44115-1405
(216) 566-9700
Customer No. 007609
Attachment: Marked-up version of Amendments

-Tyr-R₆ -(Asn-Gln)-(Y)

{(f)} SEQ ID NO: 11 (X)-Tyr-Tyr-R₃ -Pro-R₄-Asp-R₅ -Tyr-R₆

-(Asn-Gln)-Z-(Gly)-Ala-Val-Val-Gly-Gly-Leu-Gly-Gly-Tyr-(R₁₃)-(Y)

where X and Y are arbitrary amino-acid sequences, Z is a conventional spacer such as Gly-Gly, R₃ = Arg or Lys, R₄ = Met, Val or Ala, R₅ = Gln, Glu or Arg, R₆ = Ser or Asn and R₁₃ = Met or Val, and where the sequence zones in parentheses need not necessarily be present.

13. (Twice amended) A pharmaceutical preparation, a diagnostic means or vaccine as claimed in claim 1, characterized in that the PrP^{Sc} - binding substance it contains is a recombinantly produced rbPrP of the formula of ~~{Fig. 4}~~ SEQ ID NO: 12 or in the form of genus-specific deviations thereof.

IN THE ABSTRACT:

The Abstract of the Disclosure has been amended as follows:

ABSTRACT OF THE DISCLOSURE

A synthetic polypeptide containing one or more defined sequences of PrP or derivative sequences that are recognized by PrP^{Sc}-binding substances.

IN THE CLAIMS:

The claims have been amended as follows:

2. (Amended) Synthetic polypeptide as claimed in claim 1, wherein the sequence corresponds to one of the following formulas, containing at least one of the said sequences or a combination of several sequences:

{{a}} SEQ ID NO: 1 Gly-R₁-Asp-R₂-Glu-Asp-Arg-(Tyr-Tyr)

{{b}} SEQ ID NO: 2 (Gln)-(Val)-Tyr-Tyr-R₃-Pro-R₄-Asp-R₅-Tyr-R₆-(Asn-Gln)

{{c}} SEQ ID NO: 3 Cys-R₇-Thr-Gln-Tyr-R₈-R₉-Glu-Ser-R₁₀-Ala-(R₁₁-Tyr)

{{d}} SEQ ID NO: 4 (Tyr-Arg)-Glu-Asn-Met-R₁₂-Arg-Tyr-Pro-Asn-(Gln-Val-Tyr)

where R₁ = Asn or Ser, R₂ = Trp or Tyr, R₃ = Arg or Lys, R₄ = Met, Val or Ala, R₅ = Gln, Glu or Arg, R₆ = Ser or Asn, R₇ = Val, Thr or Ile, R₈ = Gln or Glu, R₉ = Lys, Arg or Gln, R₁₀ = Gln or Glu, R₁₁ = Tyr, Ser or Ala and R₁₂ = His, Tyr or Asn, and where the amino acids in parentheses are not mandatorily present.

3. (Amended) Synthetic polypeptide as claimed in claim 1, wherein the sequence corresponds to one of the following formulas, containing at least one of the said sequences or a combination of several sequences:

{{e}} SEQ ID NO: 5 Gly-Trp-Gly-Gln-Pro-His-Gly-Gly-Gly-Trp-Gly-Gln-Pro-His-Gly

{{f}} SEQ ID NO: 6 Lys-Pro-R₁₄-Lys-Pro-Lys-Thr-R₁₄-R₁₅-Lys-His-R₁₆-Ala-Gly

{{g}} SEQ ID NO: 7 Tyr-R₁₆-Leu-Gly-Ser

{{h}} SEQ ID NO: 8 Ser-Ala-Met-Ser-Arg-Pro-R₁₇-R₁₇-His-Phe-Gly-R₁₄-Asp

{{i}} SEQ ID NO: 9 Asn-Met-R₁₈-Arg-Tyr-(Pro-R₁₄)-(Gln-Val-Tyr-Tyr-R₁₉)

where R₁₄ = Asn or Ser, R₁₅ = Met, Leu or Phe, R₁₆ = Met or Val, R₁₇ = Ile, Leu or Met, R₁₈ = His, Tyr or Asn and R₁₉ = Lys or Arg and where the amino acids or sequence zones in parentheses are not mandatorily present.

6. (Twice amended) Synthetic polypeptide as claimed in claim 2, corresponding to one of the following formulas:

{{e}} SEQ ID NO: 10

(X)-(Gly)-Ala-Val-Val-Gly-Gly-Leu-Gly-Gly-Tyr-(R₁₃)-Z-Tyr-Tyr-R₃-Pro-R₄-Asp-R₅

SYNTHETIC POLYPEPTIDE FOR DIAGNOSING AND TREATING PRION-RELATED DISEASES

BACKGROUND OF THE INVENTION

[0001] The present invention relates to synthetic polypeptides and applies in particular to the diagnosis, prevention and therapy of several communicable, degenerative, neurological illnesses. Such illnesses are generically called spongiform encephalopathies, also prion illnesses. They occur in different mammals, for instance in the form of scrapie in sheep, BSE in cows and kuru or Jakob-Creutzfeld disease in humans.

[0002] The only molecule associated with the infecting agent found so far is a disease-specific prion protein (PrP^{Sc}) which is an anomalous isoform of a normal host protein (PrP^{C}) of unknown function. Both isoforms PrP^{Sc} and PrP^{C} coincide with respect to molecular weight and amino-acid sequence. They differ in the spatial folding and by their properties. Illustratively whereas PrP^{C} predominantly comprises α -helical secondary structures, and is soluble and protease-digestible, PrP^{Sc} comprises foremost β -sheet structures, and is insoluble and can be degraded only partly by proteases. Many indices, in particular the absence of other molecules except PrP^{Sc} , in the prion, and foremost the absence of nucleic acids, indicate that PrP^{C} assumes a significant (if not the main) role in initiating the above diseases. It is assumed that PrP^{C} proteins are able to convert normal PrP^{C} proteins into the disease-specific folding, thus explaining the infectiousness of PrP^{Sc} proteins.

[0003] Accordingly it appears very promising to develop therapies and diagnoses based on {

[0004]— PrP^{Sc} as the central disease molecule.

SUMMARY OF THE INVENTION

[0005] Accordingly ~~[the]~~, an objective of the invention is to create synthetic polypeptides offering the immunogenic properties, or in general the binding properties of PrP^{Sc} though free of its infectiousness.

[0006] ~~[This problem is solved by synthetic polypeptides defined in claim 1.~~

[0007] ~~—~~These are polypeptides containing one or more defined PrP sequences, where PrP denotes the prion protein generally independently of its conformation, these sequences being recognized by PrP^{Sc}-binding substances for instance in the mapping experiments which are described further below. There are a large number of different specifically PrP^{Sc}-binding substances. Examples are cited further below.

[0008] In summary the synthetic polypeptides of the invention therefore include at least one sequence which, in the native PrP^{Sc} is affixed to its surface where, alone or in combination with further sequences applicable within the scope of the invention, it shall form a binding site. At least one of the two β -sheet structures, or both, present in the structural model of the recombinant PrP, participate(s) in the formation of said PrP^{Sc}-specific surface structures. It is assumed that these structures act as a nucleation site in the PrP^{Sc} in the surface formation.

[0009] Synthetic polypeptides simulating binding sites present in the native PrP^{Sc} may be significant both in the therapy or diagnosis as well as regards prevention and other applications.

BRIEF DESCRIPTION OF THE DRAWINGS

[0010] Fig. 1 illustrates the results of an experiment according to the present invention;

[0011] Fig. 2 shows the result of a mapping experiment of which the conditions correspond to the experiment represented in Fig. 1; and,

[0012] Fig. 3 shows the corresponding peptide bank with the dyed binding zones from which, as stated above, the sequences identified as SEQ ID NOS: 5-9 were determined.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] The invention in particular includes synthetic polypeptides comprising one or several of the following sequence segments ~~{stated in claim 2:}~~:

[0014] ~~{{a}}~~ SEQ ID NO: 1 Gly-R₁-Asp-R₂-Glu-Asp-Arg-(Tyr-Tyr)

[0015] ~~{{b}}~~ SEQ ID NO: 2 (Gln)-(Val)-Tyr-Tyr-R₃ -Pro-R₄-Asp-R₅
-Tyr-R₆-(Asn-Gln)

[0016] ~~{{c}}~~ SEQ ID NO: 3 Cys-R₇ -Thr-Gln-Tyr-R₈ -R₉-Glu-Ser-R₁₀-Ala-(R₁₁ -
Tyr)

[0017] ~~{{d}}~~ SEQ ID NO: 4
(Tyr-Arg)-Glu-Asn-Met-R₁₂-Arg-Tyr-Pro-Asn-(Gln-Val-Tyr)

[0018] where R₁= Asn or Ser, R₂= Trp or Tyr, R₃ = Arg or Lys, R₄ = Met, Val or Ala, R₅ = Gln, Glu or Arg, R₆ = Ser or Asn, R₇ = Val, Thr or Ile, R₈ = Gln or Glu, R₉ = Lys, Arg or Gln, R₁₀ = Gln or Glu, R₁₁ = Tyr, Ser or Ala and R₁₂ = His, Tyr or Asn, and where the amino acids in parentheses are not mandatorily present.

[0019] ~~{According to claim 3, further}~~ Further synthetic polypeptides used within the invention may contain one or more of the following sequences:

[0020] ~~{{e}}~~ SEQ ID NO: 5
Gly-Trp-Gly-Gln-Pro-His-Gly-Gly-Gly-Trp-Gly-Gln-Pro-His-Gly

[0021] ~~{{f}}~~ SEQ ID NO: 6
Lys-Pro-R₁₄-Lys-Pro-Lys-Thr-R₁₄-R₁₅-Lys-His-R₁₆-Ala-Gly

[0022] ~~{{g}}~~ SEQ ID NO: 7 Tyr-R₁₆-Leu-Gly-Ser

[0023] ~~{{h}}~~ SEQ ID NO: 8
Ser-Ala-Met-Ser-Arg-Pro-R₁₇-R₁₇-His-Phe-Gly-R₁₄-Asp

[0024] ~~{{i}}~~ SEQ ID NO: 9
Asn-Met-R₁₈-Arg-Tyr-(Pro-R₁₄)-(Gln-Val-Tyr-Tyr-R₁₉)

[0025] where R₁₄ = Asn or Ser, R₁₅ = Met, Leu or Phe, R₁₆= Met or Val, R₁₇ = Ile, Leu or Met, R₁₈ = His, Tyr or Asn and R₁₉ = Lys or Arg and where the amino acids or sequence zones in parentheses are not mandatorily present.

[0026] The sequences ~~[of claims 2 and 3]~~ identified by SEQ ID NOS: 1-9 were found in so-called mapping experiments on an immobilized peptide bank. As regards the peptide bank used (available from Jerini Biotools, Berlin), 104 peptides with 13 amino acids each are affixed by their C-terminal ends to a cellulose membrane. They cover the full sequence of PrP (hereafter PrP denotes generally the prion protein's basic amino-acid sequence regardless of conformation) and are configured in such a way as to be shifted each time by two amino acids, that is, each time 11 amino acids overlap between two adjacent peptide banks. In the course of several mapping experiments, peptide banks were loaded with different substances binding PrP^{Sc}, and the binding of these substances to special sequence zones was made visible using for instance a chemiluminescence kit (ECL, Amersham, USA).

[0027] In order to determine the sequences ~~[claimed in claim 2]~~ identified by SEQ ID NOS: 1-4, a PrP^{Sc}-specific antigen denoted by 15B3 and (as found in our own pretesting, an also PrP^{Sc}-specific) recombinant bovine PrP (rbPrP) with the sequence shown in ~~[Fig. 4]~~ SEQ ID NO: 12 were used as the PrP^{Sc} binding substances. To prepare rbPrP, illustratively a cell line (for instance E. coli) may be cultured with a vector expressing rbPrP in a suitable medium (for instance Luria broth) and then the prion protein may be isolated after being lysed from the cell inclusion bodies by further conventional purification procedures (see Hornemann et al, FEBS Letters 97, 413 (2; 277-281)).

[0028] 15B3 is a monoclonal PrP^{Sc} antibody recently discovered by the inventors. Hybridoma cells producing the said (PrP^{Sc} - specific) antibodies 15B3 were filed on 13 February 1997 as DSM ACC2298 at the German Collection of Microorganisms and Cell Cultures GmbH in Brunswick.

[0029] In both cases, the two differently binding substances, that is, the antibody 15B3 and the recombinant rbPrP, recognized as the same the sequences ~~[a-d of claim 1]~~ SEQ ID NOS: 1-4, as reproduced for 15B3 in Fig. 1 and for rbPrP in Fig. 2.

[0030] The numerals shown in Figs. 1 and 2 denote the different bank peptide sequences bound by the monoclonal antibody 15B3 and rbPrP. The sequences of the invention each correspond the zones common to the particular spatially adjacent

binding peptides. As already mentioned, Fig. 2 shows the result of a mapping experiment of which the conditions correspond to the experiment represented in Fig. 1. In this instance the antibody 15B3 was merely replaced with recombinant bovine rbPrP. Because technical difficulties preclude better reproduction of the binding sites of the recombinant rbPrP, they are emphasized by marks. These are binding sites coinciding with those of Fig. 1.

[0031] The sequences ~~[stated in claim 3 also were]~~ identified by SEQ ID NOS: 5-9 were also determined by mapping experiments. However, in this instance the recognizing substance is not an antibody or rbPrP, but instead it is the Congo Red dye of which the specific binding relating to PrP^{Sc} has already been known for some time (Prusiner et al, Cell 35, 349-358, 1983). Fig. 3 shows the corresponding peptide bank with the dyed binding zones from which, as stated above, the sequences ~~[e-i]~~ identified as SEQ ID NOS: 5-9 were determined.

[0032] It is clear from Figs. 1-3 that the sequences a-d and e-i are not linearly related PrP sequences. As regards a 3-D model of a C-terminal fragment of recombinant mouse PrP, it was found that two of the sequences ~~[a-d stated in claim 2]~~ identified by SEQ ID NOS: 1-4 are spatially close to each other. It may be assumed with high probability that when the conformation is altered, the other two sequences also will assume another position in such a way that probably all four sequences a-d shall be configured near one another in the PrP^{Sc} and are highly likely to form a conformational epitope.

[0033] Accordingly, the claimed sequences represent sequence zones recognized individually in a peptide bank for instance by a PrP^{Sc}-specific antibody and which moreover very probably constitute, individually or severally, a surface binding site, for instance an epitope, in the native PrP^{Sc}-protein. The expression "epitope" denotes the specific antigen site on the surface of the PrP^{Sc}-protein which illustratively can be bound by the idio type of 15B3.

[0034] As a result the invention prepares synthetic polypeptides which at a minimum contain one of the said PrP^{Sc}-binding substances in the sequences recognized in the peptide bank, as well as any additional ones.

[0035] Synthetic polypeptides comprising a PrP^{Sc} antigen zone already have been disclosed in the patent document WO 93/11153. The sequences stated therein represent comparatively substantial segments of the PrP sequence. The precise boundary of a sequence for instance forming an epitope or participating in it, is lacking, and this feature hampers or makes impossible in particular the spatial buildup of minimal synthetic polypeptides having for instance the immunogen effect of PrP^{Sc}.

[0036] As discussed above, at a minimum, the synthetic peptides may be composed merely of one of the sequences ~~{claim 2}~~ of SEQ ID NOS: 1-4 or one of the cited ones. However, they may also be bound to further, suitable sequences which hereafter are called conformation sequences.

[0037] Theoretically, the sequences, for instance, might be connected to each other illustratively by means of said conformation sequences and possibly by further sequences in such manner as to stimulate the presumed spatial configuration in the PrP^{Sc} protein. Ideally a protein (epitope) would be attained in this manner which would contain several neighboring binding sites as is the case for the PrP^{Sc}.

[0038] However, in one implementation of the invention, only one of the claimed sequences ~~{(sequence b)}~~ (SEQ ID NO: 2) shall be so connected to a conformation sequence that a synthetic polypeptide is made that offers adequate binding for instance regarding 15B3, as confirmed by the inventors' tests. A polypeptide of such a configuration may include one of the two following sequences:

[0039] ~~{(f)}~~ SEQ ID NO: 10

(X)-(Gly)-Ala-Val-Val-Gly-Gly-Leu-Gly-Gly-Tyr-(R₁₃)-Z-Tyr-Tyr-R₃-Pro-R₄-Asp-R₅-Tyr-R₆- (Asn-Gln)-(Y)

[0040] ~~{(k)}~~ SEQ ID NO: 11 (X)-Tyr-Tyr-R₃-Pro-R₄-Asp-R₅-Tyr-R₆

-(Asn-Gln)-Z-(Gly)-Ala-Val-Val-Gly-Gly-Leu-Gly-Gly-Tyr-(R₁₃)-(Y)

[0041] where X and Y are arbitrary amino-acid sequences, Z is a conventional spacer, for instance Gly-Gly, R₃ = Arg or Lys, R₄ = Met, Val or Ala, R₅ = Gln, Glu or Arg, R₆ = Ser or Asn and R₁₃ = Met or Val and where the sequence zones in parentheses are not mandatorily present.

[0042] ~~[The j-sequence]~~ SEQ ID NO. 10 contains in its C-terminal zone the sequence ~~[b]~~ identified by SEQ ID NO: 2, which is connected for instance by means of the spacer Gly-Gly to the adjoining N-terminal conformation sequence. The order is exactly the opposite in the ~~[k]~~ sequence identified by SEQ ID NO: 11. Other appropriate spacers in general are those assuring adequate flexibility between the connected peptide zones and exerting no influence on conformation.

[0043] Both preferentially used synthetic peptides were designed on the findings that β sheet structures occur in increased manner in PrP^{Sc}, practically always a conformation sequence inducing a β sheet structure being present up or down the sequence. The synthetic polypeptides ~~[of claim 6 therefore were provided as claimed in claim 6]~~ identified as SEQ ID NOS: 5-6, therefore, were provided with suitable conformation sequences in order to configure the epitope sequence in a β sheet structure specific for PrP^{Sc}.

[0044] In well known manner, depending on their size, polarity or charge, amino acids may be assigned into different groups. The amino acids within one group are said to be mutually homologous and there are five groups:

[0045] (1) small aliphatic, non-polar or only slightly polar acids: alanine, serine, threonine, and, within limits, glycine, proline

[0046] (2) polar, negatively charged acids and their amides: aspergillic acid, asparagine, glutamic acid and glutamine

[0047] (3) polar, positively charged acids: histidine, arginine, lysine

[0048] (4) large aliphatic, non-polar acids: methionine, leucine, isoleucine, valine, cysteine,

[0049] (5) large aromatic acids: phenylalanine, tyrosine, tryptophane.

[0050] In many cases it is possible to replace amino acids contained in peptide sequences by corresponding acids from the same group without thereby entailing a change in sequence properties. Therefore the invention also includes those sequences that do not correspond to the explicitly stated formulas but wherein one or more amino acids were replaced by a homologous acid.

[0051] Another justifiable assumption is that independently of their direction of formation, amino-acid sequences under given circumstances may offer similar binding properties, in particular antibody binding properties. In such a case they are called "retro-aminoacid

sequences" which denote coinciding sequences formed in a C terminal or N terminal direction (for instance [N-terminal]- Glu-Ala-Val-Leu-[C-terminal], [N-terminal]-Leu-Val-Ala-Glu - [C-terminal]). If the amino acids being used are present in D chiral form opposite the L form of animals, then the epitope zones will be mirror symmetrical and shall also be recognized by a few antibodies, the isotypes of these antibodies differing in these properties. In such cases the terminology is "inverso-aminoacid-sequences. When both inverso and retro amino acids are used, there will be for instance coinciding epitope zones which can be unrestrictedly bound of the antibody which is specific to the original sequence. The advantage offered for instance by such retro-inverso sequences of amino acids is that the D amino acids are degraded more slowly by the organism because being recognized more poorly by the degrading enzymes. The same effect can also be achieved by substituting non-natural amino acids. Therefore the peptides of the invention also may be in retro- and/or inverso form and moreover they may contain non-natural amino acids, that is not produced by organisms. Non-natural amino acids may be prepared by synthesizing for instance additional side chains or reactive groups in a manner to offer specific properties and matched to specific applications.

[0052] As already discussed above, the synthetic polypeptides of the invention may be used in particular in the treatment, prevention or also diagnosis of prion diseases.

[0053] A particular application is to use the synthetic polypeptides of the invention as vaccines. Illustratively an appropriate quantity of peptide is dissolved using Freund's complete adjuvant injecting it sub-cutaneously or intra-muscularly. At intervals of several weeks, again an immunogenic quantity of peptide is dissolved in Freund's incomplete adjuvant and is injected (boost). The objective of this vaccination is to induce an immune response, including endogenous production of antibodies able to specifically recognize PrP^{Sc} and neutralize or characterize it, whereby the body's own defense mechanism shall be able to forestall disease or slow it or stop it.

[0054] Another application consists in using the synthetic polypeptides in diagnosis and therapy. In the light of the prevailing conversion theory, it is assumed the PrP^{Sc} and/or PrP^C also bind to each other. This supposition is supported by further mapping experiments by the inventors showing (Fig. 2) that recombinant bovine rbPrp binds to sequence zones similar to those that the above antibody 15B3 binds with.

[0055] The said binding properties may be put to use for instance in therapy. Conceivably the polypeptides may be cerebrally applied to an ill patient and there they shall

be available as a binding partner to the infectious PrP^{Sc}. In this manner the conversion rate might be sharply reduced and the progress of the disease slowed down. As regards diagnosis, any PrP^{Sc} contained in sample material might be specifically bound by means of the polypeptides of the invention and then be detected in appropriate manner.

[0056] The synthetic polypeptides of the invention are not restricted to the above cited sequences. Illustratively peptides in derivative form also are applicable. Illustratively such peptides might be bound to a carrier, or immunogen, such as diphtheriatoxin or BSA to enhance the immune response. Another way to make derivatives is by linking to markers, for instance using biotine or peroxidase or enzymes or nucleic acids. Lastly, signal sequences might be used to facilitate the passage of the peptides into desired compartments. This latter application relates in particular to the blood/brain barrier which might be easier to cross when using signal sequences binding the transferrin receptor.

[0057] As already stated above, the synthetic polypeptides of the invention are applicable to the therapy, diagnosis and prophylaxis of prion diseases. In conjunction with all said applicabilities, it is essential that the polypeptides of the invention be administered to the patients per se or in combination with further substances, and, as already mentioned, derivatives may be used to enhance the directionality into specific compartments.

[0058] The polypeptides may be manufactured in arbitrary manner: either directly through conventional peptide-syntheses or also indirectly through RNA or DNA synthesis and then by conventional molecular-biological techniques. Accordingly another feature of the invention relates to a DNA molecule which is able to code one of the polypeptides of the invention. Preferably such a DNA molecule (where called for also in a longer sequence) is made available in an appropriate expression vector. The routines involved are conventional.

[0059] The invention furthermore relates to a kit to diagnose PrP^{Sc} or antigens against PrP^{Sc} and containing at least one of the polypeptides of the invention. This feature avails itself of the fact that the polypeptides can specifically bind with the PrP^{Sc} and with the antibodies pointing at it.

[0060] As already mentioned, one of the substances used to ascertain the polypeptide sequences may be recombinant bovine rbPrP. Surprisingly it was found that recombinant rbPrP is able to specifically bind to PrP^{Sc} and to recognize, at the corresponding peptide bank, the same sequences as the antibodies 15B3 (see Fig. 2).

[0061] Another feature of the invention therefore relates to the use of recombinant rbPrp corresponding to the sequence SEQ ID NO: 12: ~~of Fig. 4. It was found that PrP^{Sc}-specific~~

~~antibodies are produced when administering recombinant bovine rbPrP of the indicated sequence. This effect can be exploited in particular with respect to prophylaxis or therapy in that recombinant rbPrP prepared as a vaccine is administered to a patient and thereby a corresponding immune response shall be triggered.~~

~~[0062]— Obviously the implementation is not restricted to using bovine rbPrP per Fig. 4. Recombinant PrP sequences with species-specific deviations from the rbPrP sequence shown in Fig. 4 may be used just as well.~~

~~[0063]— Lastly the invention relates also to a method for manufacturing PrPSc-specific antibodies. For purposes of immunization, at least one of polypeptides of the invention is administered in a dose sufficient for immunization to non-human mammals and the antibody thereby formed is then isolated in conventional manner.~~

~~[0064]— Lastly the peptides of the invention also are suitable for the so-called pharmaceutical or chemical libraries whereby new active ingredients are tested or determined which shall specifically bind PrPSc.~~

~~[0065]— SEQUENCE PROTOCOL~~

~~[0066]— (1) General data~~

~~[0067]— (i) Applicants~~

~~[0068]— (a) Name: Prionics AG~~

~~[0069]— (b) Wintherturerstr. 190~~

~~[0070]— (c) Zuerich~~

~~[0071]— (d) [state] Zuerich~~

~~[0072]— (e) Switzerland~~

~~[0073]— (f) postal code: CH-8090~~

~~[0074]— (a) Name: Carsten KORTH~~

~~[0075]— (b) 1534 Cole Street~~

~~[0076]— (c) San Francisco~~

~~[0077]— (d) California~~

~~[0078]— (e) USA~~

~~[0079]— (f) CA 94117~~

~~[0080] (a) Name: Bruno OESCH~~

~~[0081] (b) Haldenstr. 13~~

~~[0082] (c) Stilli~~

~~[0083] (e) Switzerland~~

~~[0084] (f) postal code: CH-5233~~

~~[0085] (a) Name, Markus MOSER~~

~~[0086] (b) Waidfuss-Str. 25~~

~~[0087] (c) Zuerich~~

~~[0088] (d) [state] Zuerich~~

~~[0089] (e) Switzerland~~

~~[0090] (f) postal code: CH-8037~~

~~[0091] (ii) Title of Invention: Synthetic polypeptide for diagnosing and treating
prion-related diseases:~~

~~[0092] (iii) Number of sequences: 4~~

~~[0093] (iv) Computer readable version:~~

~~[0094] (a) data medium: floppy disk~~

~~[0095] (b) computer: IBM PC-compatible~~

~~[0096] (c) operating system: PC-DOS/MS-DOS~~

~~[0097] (d) software: PatentIn Release # 1.0, version #1.30 (EPA)~~

~~[0098] (vi) Data of first application:~~

~~[0099] (a) Application # DE 19741607.1~~

~~[0100] (b) Date of application: 20 September 1997~~

~~[0101] (2) DATA RELATING TO SEQ ID # 1:~~

~~[0102] (i) SEQUENCE CHARACTERISTICS~~

~~[0103] (a) Length: 219 amino acids~~

~~[0104] (b) Species: Amino acid~~

~~[0105] (c) Form of strand: single strand~~

~~[0106] (d) Topology: Linear~~

~~[0107] (ii) MOLECULE SPECIES: protein~~

~~[0108] (iii) hypothetical: yes~~

~~[0109] (iv) antisense: no~~

~~[0110] (vi) PROVENANCE:~~

~~[0111] (a) organism: bos taurus~~

~~[0112] (vii) GENOME POSITION:~~

~~[0113] (c) units: 219~~

~~[0114] (xi) SEQUENCE DESCRIPTION: SEQ ID #: 1-]~~

Met	Lys	Lys	Arg	Pro	Lys	Pro	Gly	Gly	Gly	Trp	Asn	Thr	Gly	Gly	Ser	1	5	10	15
Arg	Tyr	Pro	Gly	Gln	Gly	Ser	Pro	Gly	Gly	Asn	Arg	Tyr	Pro	Pro	Gln	20	25	30	
Gly	Gly	Gly	Gly	Trp	Gly	Gln	Pro	His	Gly	Gly	Gly	Trp	Gly	Gln	Pro	35	40	45	
His	Gly	Gly	Gly	Trp	Gly	Gln	Pro	His	Gly	Gly	Gly	Trp	Gly	Gln	Pro	50	55	60	
His	Gly	Gly	Gly	Trp	Gly	Gln	Pro	His	Gly	Gly	Gly	Gly	Trp	Gly	Gln	65	70	75	80
Gly	Gly	Thr	His	Gly	Gln	Trp	Asn	Lys	Pro	Ser	Lys	Pro	Lys	Thr	Asn	85	90	95	
Met	Lys	His	Val	Ala	Gly	Ala	Ala	Ala	Ala	Gly	Ala	Val	Val	Gly	Gly	100	105	110	
Leu	Gly	Gly	Tyr	Met	Leu	Gly	Ser	Ala	Met	Ser	Arg	Pro	Leu	Ile	His	115	120	125	
Phe	Gly	Ser	Asp	Tyr	Glu	Asp	Arg	Tyr	Tyr	Arg	Glu	Asn	Met	His	Arg	130	135	140	
Tyr	Pro	Asn	Gln	Val	Tyr	Tyr	Arg	Pro	Val	Asp	Gln	Tyr	Ser	Asn	Gln	145	150	155	160
Asn	Asn	Phe	Val	His	Asp	Cys	Val	Asn	Ile	Thr	Val	Lys	Glu	His	Thr	165	170	175	
Val	Thr	Thr	Thr	Thr	Lys	Gly	Glu	Asn	Phe	Thr	Glu	Thr	Asp	Ile	Lys				

			180					185					190						
Met	Met	Glu	Arg	Val	Val	Glu	Gln	Met	Cys	Ile	Thr	Gln	Tyr	Gln	Arg				
		195					200					205							
Glu	Ser	Gln	Ala	Tyr	Tyr	Gln	Arg	Gly	Ala	Ser									
	210					215													

[0115] It was found that PrP^{Sc} specific antibodies are produced when administering recombinant bovine rbPrP of the indicated sequence. This effect can be exploited in particular with respect to prophylaxis or therapy in that recombinant rbPrP prepared as a vaccine is administered to a patient and thereby a corresponding immune response shall be triggered.

[0116] Obviously the implementation is not restricted to using bovine rbPrP per SEQ ID NO: 12. Recombinant PrP sequences with species-specific deviations from the rbPrP sequence shown in SEQ ID NO: 12 may be used just as well.

[0117] Lastly the invention relates also to a method for manufacturing PrP^{Sc}-specific antibodies. For purposes of immunization, at least one of polypeptides of the invention is administered in a dose sufficient for immunization to non-human mammals and the antibody thereby formed is then isolated in conventional manner.

[0118] Lastly the peptides of the invention also are suitable for the so-called pharmaceutical or chemical libraries whereby new active ingredients are tested or determined which shall specifically bind PrP^{Sc}.